Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
Recruiting
Early Phase 1
Interventional Study
Androgenetic Alopecia (AGA)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 40
- Sex
- Female
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is:
• Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA.
Participant…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Clinically diagnosed with androgenetic alopecia (AGA)
* No pregnancy plans within the next 6 months
Exclusion Criteria:
* Patients who received systemic medications for hair loss within the past 2 months
* Use of topical medication for hair loss within the past 2 weeks
* Pre…
Contacts